Tags

Type your tag names separated by a space and hit enter

Bioavailability, antipsoriatic efficacy and tolerability of a new light cream with mometasone furoate 0.1%.
Skin Pharmacol Physiol. 2012; 25(3):133-41.SP

Abstract

Mometasone furoate, a potent glucocorticoid (class III) with a favorable benefit/risk ratio, has emerged as a standard medication for the treatment of inflammatory skin disorders. The purpose of the investigation presented here was to determine the noninferiority of a topical mometasone formulation, a light cream (O/W 60/40 emulsion) with mometasone furoate 0.1% (water content of 33%) versus marketed comparators. Using the vasoconstrictor assay, a strong blanching effect of the new cream (called Mometasone cream) comparable to that of a mometasone comparator, a fatty cream with mometasone furoate 0.1%, could be demonstrated. Thus, the topical bioavailability of the active ingredient mometasone furoate (0.1%) was regarded to be similar for Mometasone cream and the mometasone comparator. Using the psoriasis plaque test, a strong antipsoriatic effect comparable to that of the mometasone comparator was found for Mometasone cream after 12 days of occlusive treatment. A nearly identical reduction in the mean infiltrate thickness and similar mean AUC values were noted with both formulations confirmed by clinical assessment data. The noninferiority of Mometasone cream to its active comparator with respect to the AUC of change to baseline in infiltrate thickness was demonstrated. Both medications were well tolerated. Overall, Mometasone cream and the mometasone comparator showed similar efficacy and tolerability. Mometasone cream, in addition to its high potency and good tolerability, provides the properties of a light cream, which might make this new medication particularly suitable for application on acutely inflamed and sensitive skin.

Authors+Show Affiliations

Department of Dermatology and Allergology, Ludwig Maximilian University, Munich, Germany. H.C.Korting@lrz.uni-muenchen.deNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22353786

Citation

Korting, H C., et al. "Bioavailability, Antipsoriatic Efficacy and Tolerability of a New Light Cream With Mometasone Furoate 0.1%." Skin Pharmacology and Physiology, vol. 25, no. 3, 2012, pp. 133-41.
Korting HC, Schöllmann C, Willers C, et al. Bioavailability, antipsoriatic efficacy and tolerability of a new light cream with mometasone furoate 0.1%. Skin Pharmacol Physiol. 2012;25(3):133-41.
Korting, H. C., Schöllmann, C., Willers, C., & Wigger-Alberti, W. (2012). Bioavailability, antipsoriatic efficacy and tolerability of a new light cream with mometasone furoate 0.1%. Skin Pharmacology and Physiology, 25(3), 133-41. https://doi.org/10.1159/000335656
Korting HC, et al. Bioavailability, Antipsoriatic Efficacy and Tolerability of a New Light Cream With Mometasone Furoate 0.1%. Skin Pharmacol Physiol. 2012;25(3):133-41. PubMed PMID: 22353786.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bioavailability, antipsoriatic efficacy and tolerability of a new light cream with mometasone furoate 0.1%. AU - Korting,H C, AU - Schöllmann,C, AU - Willers,C, AU - Wigger-Alberti,W, Y1 - 2012/02/17/ PY - 2011/07/22/received PY - 2011/12/06/accepted PY - 2012/2/23/entrez PY - 2012/2/23/pubmed PY - 2012/9/8/medline SP - 133 EP - 41 JF - Skin pharmacology and physiology JO - Skin Pharmacol Physiol VL - 25 IS - 3 N2 - Mometasone furoate, a potent glucocorticoid (class III) with a favorable benefit/risk ratio, has emerged as a standard medication for the treatment of inflammatory skin disorders. The purpose of the investigation presented here was to determine the noninferiority of a topical mometasone formulation, a light cream (O/W 60/40 emulsion) with mometasone furoate 0.1% (water content of 33%) versus marketed comparators. Using the vasoconstrictor assay, a strong blanching effect of the new cream (called Mometasone cream) comparable to that of a mometasone comparator, a fatty cream with mometasone furoate 0.1%, could be demonstrated. Thus, the topical bioavailability of the active ingredient mometasone furoate (0.1%) was regarded to be similar for Mometasone cream and the mometasone comparator. Using the psoriasis plaque test, a strong antipsoriatic effect comparable to that of the mometasone comparator was found for Mometasone cream after 12 days of occlusive treatment. A nearly identical reduction in the mean infiltrate thickness and similar mean AUC values were noted with both formulations confirmed by clinical assessment data. The noninferiority of Mometasone cream to its active comparator with respect to the AUC of change to baseline in infiltrate thickness was demonstrated. Both medications were well tolerated. Overall, Mometasone cream and the mometasone comparator showed similar efficacy and tolerability. Mometasone cream, in addition to its high potency and good tolerability, provides the properties of a light cream, which might make this new medication particularly suitable for application on acutely inflamed and sensitive skin. SN - 1660-5535 UR - https://www.unboundmedicine.com/medline/citation/22353786/Bioavailability_antipsoriatic_efficacy_and_tolerability_of_a_new_light_cream_with_mometasone_furoate_0_1_ L2 - https://www.karger.com?DOI=10.1159/000335656 DB - PRIME DP - Unbound Medicine ER -